Coronary heart disease (CHD) includes myocardial infarction, stable or unstable angina, demonstrated myocardial ischemia detected by noninvasive testing, and a history of coronary artery procedures (such a stent or bypass). Despite major advances in treatment of CHD patients, a large number of victims of the disease who are apparently healthy die suddenly without prior symptoms. Thus, available screening and diagnostic methods are insufficient to identify the victims before the event occurs.
In studies of nearly 50,000 subjects, Celera has discovered and replicated novel associations with several genetic variants, such as one in the kinesin 6 (KIF6) , that predicts up to 55% increased risk for CHD. We have also shown in four studies of samples from clinical trials of cholesterol-reducing drugs (statins) that statin treatment essentially eliminates this increased genetic risk.
* J Am Coll Cardiol, 2008; 51:449-455.